N-(tert-butyl)-4,5-dihydro-1H-imidazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: N-(tert-butyl)-4,5-dihydro-1H-imidazol-2-amine
• 英文别名: N-tert-butyl-4,5-dihydro-1H-imidazol-2-amine
• 化学式: C₇H₁₅N₃
• 分子量: 141.216
• InChiKey: RULWKKLGQCCJOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  36.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  叔丁基异硫氰酸酯 在 四氢吡咯 、 lead(II) oxide 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 16.0h， 生成 N-(tert-butyl)-4,5-dihydro-1H-imidazol-2-amine
  参考文献：
  名称：

  从双（硫脲）轻松合成一锅1,2,3-Tri-和1,1,2,3-四取代的Bi（胍）

  摘要：

  一锅法用于从容易获得的双（硫脲）中以良好或优异的产率获得1,2,3-三-和1,1,2,3-四取代的双（胍）。这种简便的策略用于提供包含一系列终端和桥接基团的产品。这种方法使用空间要求较低的环状和无环仲烷基胺以及伯胺和苯胺。

  DOI：

  10.1002/ejoc.201700782

文献信息

• NOVEL CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR OLIGONUCLEOTIDE DELIVERY
  申请人：Cameron Mark

  公开号：US20120253032A1

  公开（公告）日：2012-10-04

  The instant invention provides for novel cationic lipids with short lipid chains that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilitate the cellular uptake and endosomal escape, and to knockdown target mRNA both in vitro and in vivo while decreasing inflammatory toxicities.

  本发明提供了一种新型阳离子脂质，其脂肪链较短，可以与其他脂质成分（如胆固醇和PEG脂质）结合，形成脂质纳米粒子，用于寡核苷酸的细胞摄取和内体逃逸，并在体内外降低炎症毒性的同时靶向降低目标mRNA。
• Beta Amino Acid Derivatives as Integrin Antagonists
  申请人：Saint Louis University

  公开号：US20140038910A1

  公开（公告）日：2014-02-06

  Disclosed herein are novel pharmaceutical agents which are useful as integrin receptor antagonists that mediate the pathologic processes of angiogenesis and fibrosis and as such are useful in pharmaceutical compositions and in methods for treating conditions mediated by these integrins by inhibiting or antagonizing these integrins. The novel pharmaceutical agents include those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods and intermediates useful for making the pharmaceutical agents and methods of using the pharmaceutical agents are also provided.

  本文揭示了一种新型药物，它们可用作整合素受体拮抗剂，介导血管生成和纤维化的病理过程，并且因此可用于制备药物组合物和治疗通过抑制或拮抗这些整合素介导的疾病的方法。这些新型药物包括以下公式中的药物：其中变量在此定义。还提供了包含这些药物的制药组合物、试剂盒和制品。还提供了用于制造药物的方法和中间体以及使用药物的方法。
• Bis-benzimidazole compounds and methods of using the same
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US10961202B2

  公开（公告）日：2021-03-30

  Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.

  本文提供了用于调节基因序列异常重复扩增的化合物和方法。更具体地说，本文提供了 RNA 的抑制剂以及此类抑制剂在调节核苷酸重复扩增中的用途，例如，用于治疗肌营养不良症 1 型 (DM1)、肌营养不良症 2 型 (DM2)、福氏营养不良症、亨廷顿氏病、肌萎缩侧索硬化症或额叶痴呆症。
• N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS
  申请人：Sinha Santosh C.

  公开号：US20130029994A1

  公开（公告）日：2013-01-31

  The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
• BIS-BENZIMIDAZOLE COMPOUNDS AND METHODS OF USING THE SAME
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20190152924A1

  公开（公告）日：2019-05-23

  Provided herein are compounds and methods for modulating abnormal repeat expansions of gene sequences. More particularly, provided are inhibitors of RNA and the uses of such inhibitors in regulating nucleotide repeat expansions, e.g., to treat Myotonic Dystrophy Type 1 (DM1), Myotonic Dystrophy Type 2 (DM2), Fuchs dystrophy, Huntington Disease, Amyotrophic Lateral Sclerosis, or Frontotemporal Dementia.